FTC’s Challenge to Amgen-Horizon Merger Sparks Industry Attention

The Federal Trade Commission (FTC) is delaying the closure of Amgen's acquisition of Horizon Therapeutics, as both companies now aim to complete the merger by mid-December 2023. The FTC alleges that Amgen could use its drug portfolio to reinforce monopolistic positions for Horizon’s Tepezza and Krystexxa treatments where there are few competitors in these spaces. A federal court placed a tempora..